SPC
PDLI

Sigma Planning Corp’s PDL BioPharma, Inc. PDLI Stock Holding History

Sigma Planning Corp’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-63,315
Closed -$445K – 806
2015
Q1 		$445K Buy
+63,315
New +$459K 0.06% 378

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sigma Planning Corp's PDLI Position: Q2 2015 in Review

Sigma Planning Corp sold out of PDL BioPharma, Inc. (PDLI) in Q2 2015, closing a stake of 63,315 shares — an estimated $445K sold.

Sigma Planning Corp first reported a position in PDLI in Q1 2015 and held it in 1 quarter. The position peaked at $445K in Q1 2015. 204 funds tracked by Wall St. Rank hold PDLI as of Q2 2015.

  • Sigma Planning Corp reported no remaining PDL BioPharma, Inc. position as of Q2 2015 after selling out during the quarter.
  • Sigma Planning Corp sold 63,315 PDL BioPharma, Inc. shares in Q2 2015, an estimated $445K.
  • Sigma Planning Corp first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 1 quarter.
  • Sigma Planning Corp's PDL BioPharma, Inc. position peaked at $445K in Q1 2015.
  • 204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2015.

Based on Sigma Planning Corp's 13F filing for Q2 2015, filed 14 Jul 2015.